Portuguese pharmaceutical company Hovione has announced a “state-of-the-art, continuous manufacturing facility” is set to come online at its Loures site in Portugal.
The company has also established a multi-disciplinary global team in continuous tableting, while upgrading its labs with the tools needed to support the drug product lifecycle.
Jean-Luc Herbeaux, Hovione’s CEO, said: “Hovione has been historically focused on innovative technologies that benefit our customers and patients. With this investment in continuous tableting, our customers can rely on our support to bring much needed medicines to the market as fast as possible with the highest quality and manufacturing standards.”
Herbeaux added: “We are investing to accelerate the adoption of this technology as we continue to innovate and enhance our offering around our areas of expertise.”
This investment in continuous tableting from R&D to production further strengthens Hovione´s CDMO offering
The technology offers advantages including faster development of simpler processes, manufacturing for variable demand, control strategies and high process quality standards.
Filipe Neves, Hovione´s Strategic Business Director, said: “This investment in continuous tableting from R&D to production further strengthens Hovione´s CDMO offering and responds to the growing customer interest.”
Continuous manufacturing is expected to change the landscape of drug product development and commercial production. The Food and Drug Administration (FDA) is partnering with the International Council for Harmonisation and leading a global initiative to advance continuous manufacturing of small molecules and other pharmaceutical modalities.